Skip to content

Effects of intravenous Dexmedetomidine with Dexmedetomidine as nebulisation for awake intubation through nose by using flexible fiberoptic endoscope

Effect of IV versus Nebulised Dexmedetomidine on intubating conditions during Awake Fiberoptic Intubation:A Randomised Double Blind Prospective Comparative Study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/08/056201
Enrollment
60
Registered
2023-08-07
Start date
Unknown
Completion date
Unknown
Last updated
2023-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K800- Calculus of gallbladder with acutecholecystitis Health Condition 2: H701- Chronic mastoiditis Health Condition 3: S024- Fracture of malar, maxillary and zygoma bones Health Condition 4: S026- Fracture of mandible Health Condition 5: S422- Fracture of upper end of humerus Health Condition 6: O- Medical and Surgical Health Condition 7: V209- Unspecified motorcycle rider injured in collision with pedestrian or animal in traffic accident

Interventions

Intervention1: Awake Fiberoptic Intubation: After study drug infusion and nebulisation,patient will be intubated by using flexible fiberoptic endoscope. Control Intervention1: Intravenous Dexmedetomid

Sponsors

Department of Anaesthesiology and Critical Care
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients ASA physical status Grade I and II 2.Patients undergoing elective surgery under General Anesthesia 3.Patients with Mallampati Class I and II

Exclusion criteria

Exclusion criteria: 1.Patient refusal 2.Emergency surgery 3.Patients with severe bradycardia/heart block 4.Pregnant and lactating mothers 5.Patients with contraindication to nasal intubation such as grossly distorted airway anatomy,URTI and bleeding disorders. 6.Patients with Mallampati Class III and IV

Design outcomes

Primary

MeasureTime frame
Severity of cough scoreTimepoint: 10 minutes

Secondary

MeasureTime frame
1.Intubating conditions 2.Vocal cord position 3.Ramsay sedation score 4.ComplicationsTimepoint: From starting of the study drug infusion to 24 hours postoperatively

Countries

India

Contacts

Public ContactDr Anush Jain

RNT Medical College

sharma0979@yahoo.co.in9214323557

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026